Loading organizations...
§ Private Profile · 1625 Roe Crest Dr, North Mankato, MN 56003, USA
Navitor Pharmaceuticals is a company.
Navitor Pharmaceuticals develops therapeutics by selectively modulating mTORC1, a key regulator of cell growth and metabolism. Their approach targets specific nutrient sensors to restore natural cellular responses. The pipeline includes a lead program for treatment-resistant depression, with applications spanning neurological, fibrotic, rare diseases, and immunometabolism. The company's focus is on harnessing these fundamental biological pathways for therapeutic intervention.
Co-founded in 2010 by David Sabatini, Navitor Pharmaceuticals originated from the insight that the mTOR pathway's therapeutic potential could be harnessed. By manipulating nutrient sensors governing mTORC1 activity, the founders aimed to create a new class of medicines to re-establish fundamental cellular balance. This strategy was developed from a deep scientific understanding of metabolic regulation and its role in disease pathology.
Navitor's therapeutics aim to treat patients with conditions like treatment-resistant depression, neurological impairments, and fibrotic or rare diseases. The company's vision involves advancing a robust portfolio of mTORC1-targeted treatments from discovery to validation. Their mission is to restore appropriate mTORC1 activity, improving patient outcomes for healthier, longer lives through targeted intervention.
Navitor Pharmaceuticals has raised $57.0M across 2 funding rounds.
Key people at Navitor Pharmaceuticals.
Navitor Pharmaceuticals has raised $57.0M in total across 2 funding rounds.
Navitor Pharmaceuticals has raised $57.0M across 2 funding rounds. Most recently, it raised $33.0M Series B in December 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2015 | $33M Series B | Vinzenz Ploerer | Endeavor Venture Funds, Polaris Partners, Venrock, Atlas Venture, Johnson & Johnson Innovation, Polaris Partners, Barry Burgdorf, Sanofi Ventures, SR ONE | Announced |
| Jun 1, 2014 | $24M Series A | — | Endeavor Venture Funds, Polaris Partners, Venrock, Atlas Venture, James Tobin, Longevity Fund, Alan Crane, SR ONE | Announced |
Key people at Navitor Pharmaceuticals.
Navitor Pharmaceuticals, Inc. is a biopharmaceutical company developing novel medicines that target cellular nutrient signaling pathways, specifically modulating mTORC1—a key regulator of cellular metabolism, protein synthesis, growth, and renewal—to address diseases caused by its dysregulation.[1][2][3] The company serves patients with conditions like treatment-resistant depression, cognition/memory disorders, and polycystic kidney disease, solving problems of aberrant cellular signals through its proprietary platform enabling selective mTORC1 inhibition and activation; its lead candidate, NV-5138 (an mTORC1 activator), is in Phase 2 for treatment-resistant depression, with a partnership with Supernus Pharmaceuticals announced for joint development.[2][5] Founded in 2010 in Cambridge, Massachusetts, Navitor has raised funding from investors including Sanofi Ventures, Johnson & Johnson Innovation, Atlas Venture, Brace Pharma Capital, and Polaris Partners, maintaining a small team (<25 employees) and revenue under $5 million while advancing a pipeline of small molecule drugs.[1][2]
Navitor Pharmaceuticals was founded in 2010 in Cambridge, Massachusetts, as a biotech focused on drug discovery in pharmaceuticals and health/medical sectors.[1] Its scientific foundation stems from expertise in nutrient sensing pathways, with the company emerging to pioneer mTORC1-targeted therapeutics amid growing interest in cellular metabolism's role in disease.[3] Early traction included securing investments from prominent venture firms like Sanofi Ventures, Atlas Venture, and Polaris Partners, supporting platform development; a known early employee is Casey Lumpkin, a Research Associate II.[1] Pivotal moments include advancing NV-5138 to clinical stages (Phase 2 start in 2022) and forming a joint development agreement with Supernus Pharmaceuticals for CNS applications.[2][5]
Navitor stands out in biotech through its specialized focus on mTORC1 modulation, offering:
Navitor rides the wave of precision medicine in biotech, capitalizing on trends in nutrient sensing and mTOR pathway modulation amid rising demand for therapies targeting metabolic dysregulation in aging, neurodegeneration, and rare diseases.[1][2][3] Timing aligns with advances in understanding mTORC1's role beyond cancer—into CNS disorders like depression and kidney diseases—fueled by market forces such as increasing CNS drug needs (e.g., treatment-resistant depression affecting millions) and investor interest in platform technologies with multiple indications.[2][5] By influencing the ecosystem through clinical proof-of-concept for selective mTORC1 tools, Navitor enables broader adoption in drug discovery, potentially accelerating therapies from startups and big pharma alike.[1][2]
Navitor's path forward hinges on NV-5138 Phase 2 data, which could validate mTORC1 activation for depression and unlock expansions into cognition, neuroprotection, or metabolic diseases, bolstered by its Supernus partnership.[2][5] Trends like AI-driven target discovery and personalized metabolic therapies will shape its trajectory, with potential for acquisition by larger players given its platform's versatility and VC backing.[1] As mTOR research evolves, Navitor could amplify its influence by licensing tech or advancing more assets, solidifying its role in extending healthier lifespans through cellular renewal—echoing its mission to help patients live longer via nutrient pathway innovation.[2]
Navitor Pharmaceuticals has raised $57.0M in total across 2 funding rounds.
Navitor Pharmaceuticals's investors include Vinzenz Ploerer, Endeavor Venture Funds, Polaris Partners, Venrock, Atlas Venture, Johnson & Johnson Innovation, Barry Burgdorf, Sanofi Ventures, SR One, James Tobin, Longevity Fund, Alan Crane.
